Sensorion SA Profile Avatar - Palmy Investing

Sensorion SA

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin def…

Biotechnology
FR, Montpellier [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 14% Weak
Profitability n.A. n.A.
Fin. Growth n.A. n.A.
Leverage & Liquidity 17% Weak
Per Share Metrics 67% Positive
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q2 Δ in %
EV/EBITDA -8.72 -7.02 -6.46
Graham Fair Price 33.50 0.61 0.46
PEG 0.00 0.00 0.00
Price/Book -10.58 2.16 2.42
Price/Cash Flow -102.53 -14.62 -7.22
Prices/Earnings -57.84 -3.24 -2.06
Price/Sales 115.48 57.51 26.69
Price/FCF -102.53 -14.62 -7.22
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q2 Δ in %
Gross Profit Margin -2.68 0.82 0.84
Operating Margin -99.13 0.04 -4.36
ROA 34.91 -0.14 -0.21
ROE -0.29 -0.17 43.35
ROIC -0.30 < 0.005 -99.53
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q2 Δ in %
Debt QOQ 0.00 0.00 0.00
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ 0.00 0.00 0.00
EPS QOQ 0.00 0.00 0.00
FCF QOQ 0.00 0.00 0.00
Revenue QOQ 0.00 0.00 0.00
Naive Interpretation member
03 - Financial Growth · Not Interpreted
Fundamentals

Leverage & Liquidity

Metric Q4 Q2 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 0.00 0.00 0.00
Days Sales Outstanding (DSO) 159.00 246.60 55.09
Inventory Turnover 0.00 0.00 0.00
Debt/Capitalization 0.07 0.02 -70.22
Quick Ratio 4.12 6.91 67.99
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q2 Δ in %
Book Value 0.18 0.32 77.37
Cash 0.20 0.61 210.86
Capex < 0.005 < 0.005 -38.76
Free Cash Flow -0.06 -0.05 21.69
Revenue 0.02 0.01 -26.40
Naive Interpretation member
05 - Per Share Metrics · Positive
Fundamentals

Financial Health

Metric Q4 Q2 Δ in %
Current Ratio 4.21 6.91 64.25
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA -0.11 6.26 5649.93
Naive Interpretation Member
06 - Financial Health · Bad
End of ALSEN.PA's Analysis
CIK: - CUSIP: F8312Z102 ISIN: FR0012596468 LEI: - UEI: -
Secondary Listings
ALSEN.PA has no secondary listings inside our databases.